The objective of the study was to analyze short-term outcomes and safety profile of the newly designed artificial urinary sphincters (AUSs) VICTO® and VICTOplus®.
Data from the implant of VICTO® or VICTOplus® AUSs on a series of consecutive male patients with stress urinary incontinence (SUI) following radical prostatectomy (RP) were retrospectively collected in 3 tertiary referral centers between May 2017 and December 2019. Patients were affected by moderate-severe genuine SUI (200-400 or >400 g urine leakage in 24-h pad test) refractory to conservative treatment. Outcomes were evaluated through the 24-h pad test and the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF). Follow-up was scheduled after 3, 6, and 12 months and then when clinically needed. Nonparametric tests were applied in subgroup analyses.
Seventeen patients were enrolled: 8 were implanted with the VICTO® device and 9 with VICTOplus®. The median age at surgery was 69 (interquartile range (IQR) 60-75) years. The median follow-up was 15 (IQR 12-18) months. At 12 months, the dry rate was 76.4% and the social continence rate was 94%. The postoperative complication rate was 17.6%. All complications were classified as Clavien-Dindo I. No difference in terms of outcomes was observed between the VICTO® and the VICTOplus® subgroups.
Preliminary outcomes of the VICTO® and VICTOplus® implantation are satisfactory. These devices may represent a safe and realistic solution for patients with moderate-severe SUI following RP.
Urologia internationalis. 2021 Feb 19 [Epub ahead of print]
Alessandro Giammò, Marco Falcone, Gideon Blecher, Enrico Ammirati, Paolo Geretto, Alberto Manassero, Danilo Bottero, Vito Lorusso, Diego Signorello, Paolo Gontero, Roberto Carone
Department of Neuro-Urology, CTO-Spinal Cord Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy., Department of Neuro-Urology, CTO-Spinal Cord Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy, ., Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia., Department of Urology, European Institute of Oncology (IEO), Milan, Italy., Department of Urology, Bressanone Hospital, Bressanone, Bolzano, Italy.